Ruxolitinib Vs Best Available Therapy in Patients With Steroid-Refractory/Dependent Chronic GRAFT-VS-HOST Disease (CGVHD): Subgroup Analyses of Overall Response Rate in The Phase 3 Reach3 Trial
Loading...
Date
Journal Title
Journal ISSN
Volume Title
dc.identifier.issn
dc.identifier.doi
dc.identifier.other
WOS:000668928500053
dc.description.volume
dc.description.issue
Publisher
SPRINGERNATURE